Back to search

Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER

S. Y. Jiang
DOI: 10.1210/me.6.12.2167
Molecular Endocrinology

Data up to Jan 2025

Published1992
Citations32
References0
Fields
BiologyMedicineCancer researchInternal medicineEndocrinology

Total Citations Per Year

Abstract

References (0)

No references found

Cited By (0)

Loading...
Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the… (1992) – Molecular Endocrinology | Metascience Observatory Explorer